Association between fecal S100A12 concentration and histologic, endoscopic, and clinical disease severity in dogs with idiopathic inflammatory bowel disease

Heilmann, Romy M.; Grellet, Aurélien; Allenspach, Karin; Lecoindre, P.; Day, Michael; Priestnall, Simon L.; Toresson, Linda; Procoli, Fabio; Grützner, Niels; Suchodolski, Jan S.; Steiner, Jörg M.

doi:10.1016/j.vetimm.2014.01.006

Cited by 42 publications

(82 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Coprological assays, including fecal MPO, have been used to diagnose distal GI inflammation in man and animals . In man, the fecal MPO assay has a sensitivity of 89% to detect intestinal inflammation and correlates with clinical and endoscopic response to therapy .…”

Section: Discussionmentioning

confidence: 99%

Effect of selective versus nonselective cyclooxygenase inhibitors on gastric ulceration scores and intestinal inflammation in horses

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of selective versus nonselective cyclooxygenase inhibitors on gastric ulceration scores and intestinal inflammation in horses

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Samples were stored frozen (–20°C or −80°C) until sample analysis within 2–20 months. Fecal samples were then thawed and extracted, and biomarker concentrations were measured in 2 batches of all specimens …”

Section: Methodsmentioning

confidence: 99%

Serologic and fecal markers to predict response to induction therapy in dogs with idiopathic inflammatory bowel disease

Otoni¹,

Heilmann

García-Sancho

et al. 2018

Veterinary Internal Medicne

Self Cite

View full text Add to dashboard Cite

BackgroundLittle information is available of markers that assess the disease course in dogs with idiopathic inflammatory bowel disease (IBD).ObjectivesEvaluate relationship between disease severity and serum and fecal biomarkers in dogs with idiopathic IBD before and after treatment.AnimalsSixteen dogs with idioptahic IBD and 13 healthy dogs.MethodsProspective case control study. Canine IBD activity index (CIBDAI) clinical score, serum concentrations of C‐reactive protein (CRP), perinuclear antineutrophil cytoplasmic antibodies (pANCA), and serum and fecal canine calprotectin (cCP) were measured before and after 21 days of treatment.ResultsSerum CRP (median 3.5 mg/L; range: 0.1‐52.4 mg/L), fecal cCP (median 92.3 μg/g; range: 0.03‐637.5 μg/g), and CIBDAI scores significantly increased in dogs with IBD before treatment compared with serum CRP (median 0.2 mg/L; range: 0.1‐11.8 mg/L; P < .001), fecal cCP (median 0.67 μg/g; range: 0.03‐27.9 μg/g; P < .001) and CIBDAI (P < .001) after treatment. No significant associations between CIBDAI scores and before or after treatment serum biomarkers. There was a significant association between fecal cCP and CIBDAI scores before treatment (rho = 0.60, P = .01). CRP and fecal cCP significantly decreased after treatment (median 3.5 mg/L v. 0.2 mg/L; P < .001 and 92.3 μg/g v. 0.67 μg/g; P = .001, respectively).Conclusions and Clinical ImportanceOur data indicate that measurement of fecal cCP concentration is a useful biomarker for noninvasive evaluation of intestinal inflammation. Dogs with severe signs of GI disease more often have abnormal markers than dogs having less severe disease.

show abstract

“…Fecal S100A12 concentration also appears to be a useful biomarker of gastrointestinal inflammation in dogs (Table 2). 14, 27, 45, 50, 133 Fecal canine S100A12 concentrations are correlated with the severity of clinical signs and endoscopic lesions, but not with the severity of histopathologic changes 50, 133. A fecal S100A12 concentration ≥490 ng/g can distinguish dogs requiring anti‐inflammatory or immunosuppressive treatment (IRE/NRE) from those with FRE or ARE with a sensitivity of 64% and a specificity of 77% 45.…”

Section: Biomarkers In Chronic Inflammatory Enteropathies Of Dogsmentioning

confidence: 99%

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Heilmann

Steiner

2018

Veterinary Internal Medicne

Self Cite

108

View full text Add to dashboard Cite

Chronic inflammatory enteropathies (CIE) in dogs are a group of disorders that are characterized by chronic persistent or recurrent signs of gastrointestinal disease and histologic evidence of mucosal inflammation. These CIEs are classified as either food‐responsive, antibiotic‐responsive, or immunosuppressant‐responsive enteropathy. Patients not clinically responding to immunomodulatory treatment are grouped as nonresponsive enteropathy and dogs with intestinal protein loss as protein‐losing enteropathy. Disease‐independent clinical scoring systems were established in dogs for assessment of clinical disease severity and patient monitoring during treatment. Histopathologic and routine clinicopathologic findings are usually not able to distinguish the subgroups of CIE. Treatment trials are often lengthy and further diagnostic tests are usually at least minimally invasive. Biomarkers that can aid in defining the presence of disease, site of origin, severity of the disease process, response to treatment, or a combination of these would be clinically useful in dogs with CIE. This article summarizes the following biomarkers that have been evaluated in dogs with CIE during the last decade, and critically evaluates their potential clinical utility in dogs with CIE: functional biomarkers (cobalamin, methylmalonic acid, folate, α1‐proteinase inhibitor, immunoglobulin A), biochemical biomarkers (C‐reactive protein, perinuclear anti‐neutrophilic cytoplasmic antibodies, 3‐bromotyrosine, N‐methylhistamine, calprotectin, S100A12, soluble receptor of advanced glycation end products, cytokines and chemokines, alkaline phosphatase), microbiomic biomarkers (microbiome changes, dysbiosis index), metabolomic biomarkers (serum metabolome), genetic biomarkers (genomic markers, gene expression changes), and cellular biomarkers (regulatory T cells). In addition, important performance criteria of diagnostic tests are briefly reviewed.

show abstract

Association between fecal S100A12 concentration and histologic, endoscopic, and clinical disease severity in dogs with idiopathic inflammatory bowel disease

Cited by 42 publications

References 28 publications

Effect of selective versus nonselective cyclooxygenase inhibitors on gastric ulceration scores and intestinal inflammation in horses

Effect of selective versus nonselective cyclooxygenase inhibitors on gastric ulceration scores and intestinal inflammation in horses

Serologic and fecal markers to predict response to induction therapy in dogs with idiopathic inflammatory bowel disease

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Contact Info

Product

Resources

About